Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) pre-open: I have fundamental concerns within the sector

February 4, 2019 7:58am

Indications are subdued; news is weak, where are insider’s BUYs – a sentiment indicator?

Three (3) positive closes in a row in and following January’s 22 sessions, when there were 13 positive, 1 neutral, 1 holiday and 7 negative closes

News: UniQure (QURE) had Monday morning news of treating its first patient in its HOPE-B pivotal trial of AMT-061, an investigational AAV5-based gene therapy incorporating the patent-protected FIX-Padua variant for the treatment of patients with severe and moderately severe hemophilia B. AMT-061 has been granted Breakthrough Therapy Designation by the U.S. FDA and access to Priority Medicines (PRIME) regulatory initiative by the European Medicines Agency – Maintaining BUY

Pre-open indications: 1 BUY, 2 SELLs, 1 HOLD and 3 trades

Skim if you can trim, buy if it will fly and sell if compelled!

Members only. Please login.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

2 hours 23 min ago
RegMed Investors (RMi) Closing Bell: I told you so

11 hours 11 min ago
RegMed Investors’ (RMi) pre-open: It’s “make” a buck day!

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.